NCT07117760
Phase 2 Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Phase 1/2 → Phase 2 Show 5 more changesShow less
- Enrollment increased: 16 → 24 participants
- Eligibility criteria expanded, about 26 words
- Study completion moved earlier from Dec 31, 2029 to Dec 31, 2028
- Study description expanded, about 2 words
- Study title expanded, about 1 word
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 20 to confirmed 16
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Prostate-specific antigen 50 (PSA50) response
Timeframe: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Number of participants with Treatment Emergent Adverse Events
Timeframe: From enrollment till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)
Secondary (2)
Progression Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
225Ac-LNC1011Experimental
Participant will receive 3.7 MBq (+/- 10%) 225Ac-LNC1011, once every 8-10 weeks for a planned 4 cycles
Drugs: 225Ac-LNC1011, 68Ga-PSMA-11
Sites
1 site in 1 country
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, China